Effect of timing of recurrence on outcomes in patients with metastatic breast cancer treated with CDK4/6 inhibitors. This is an ASCO Meeting Abstract from the 2024 ASCO Annual Meeting I. This abstract ...

The first-in-human phase 1/2 study of TSN1611, a highly selective KRAS G12D inhibitor, in patients with advanced solid tumors. Seizure-related homolog 6 (SEZ6) expression and ctDNA methylation ...